CSBR — CHAMPIONS ONCOLOGY, INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 771856 ·
Last close
$5.36
Market Cap
$74.47M
52W High
$7.00
52W Low
$5.22
ADV30
8,543
Next earnings
2026-09-14
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Apr 2026 | 13,835,000 | 7,025,000 | -521,000 | -667,000 | 26,989,000 | 4,872,000 | 22,921,000 |
| Jan 2026 | 16,559,000 | 7,725,000 | -187,000 | -279,000 | 28,447,000 | 7,127,000 | 24,069,000 |
| Oct 2025 | 15,035,000 | 7,773,000 | 185,000 | 299,000 | 30,162,000 | 8,516,000 | 25,931,000 |
| Jul 2025 | 13,995,000 | 6,000,000 | -507,000 | -466,000 | 30,546,000 | 10,325,000 | 27,008,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-4,472,000
Investing CF
$-540,000
Financing CF
$99,000
CapEx
$-564,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.16
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-80,400,000
Inventory
—
Receivables
$12,067,000
ST Investments
—
EBIT TTM
$-2,223,000
Pretax Income TTM
$-2,398,000
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$59,425,000
EBITDA
$348,000
Free Cash Flow
$-4,291,125
Enterprise Value
$74,324,528
Total Cash
$4,872,000
Total Debt
$4,598,000
Shares Out
13,893,569
Trailing EPS
$-0.08
Book Value
$0.28
ROE
-30.0%
ROA
-2.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Apr 2026 | 59,425,000 | -1,029,000 | -1,175,000 | 26,989,000 | 22,921,000 | — | -4,472,000 |
| Apr 2025 | 56,944,000 | 4,846,000 | 4,701,000 | 32,344,000 | 28,572,000 | — | 7,386,000 |
| Apr 2024 | 50,155,000 | -6,921,000 | -7,276,000 | 26,132,000 | 28,035,000 | — | -6,137,000 |
| Apr 2023 | 53,870,000 | -4,449,000 | -5,335,000 | 34,311,000 | 29,675,000 | — | 3,972,000 |
| Apr 2022 | 49,109,000 | 607,000 | 548,000 | 35,378,000 | 26,282,000 | — | 6,497,000 |
TTM Snapshot
Revenues TTM
$14,061,000
NetIncome TTM
$1,313,000
OpCashFlow TTM
$0
Assets (Latest)
$32,344,000
Forward EPS
$0.10
Max Pain — expiry 2026-08-21 (volume-derived — Yahoo OI feed degraded)
max pain strike: $5.00 · spot: $5.36 · call volume: 41 · put volume: 0Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ATRA | Atara Biotherapeutics, Inc. | $75.51M | $8.38 | — |
| GNTA | Genenta Science S.p.A. | $71.84M | $1.49 | — |
| CGTX | COGNITION THERAPEUTICS INC | $79.65M | $0.89 | — |
| ENZN | Viskase Holdings, Inc. | $67.50M | $4.71 | — |
| CRDF | Cardiff Oncology, Inc. | $66.90M | $0.86 | — |
News headlines (Yahoo Finance, 1h cache)
CSBR Stock Dips Post Q4 Earnings Despite Record Revenue Growth, AI Push
2026-07-30 16:15 · Yahoo
Champions Oncology Inc (CSBR) (Q4 2026) Earnings Call Highlights: Record Revenue and Positive ...
2026-07-30 03:00 · Yahoo
Champions Oncology Q4 Earnings Call Highlights
2026-07-27 22:02 · Yahoo
Champions Oncology Reports Record Annual Revenue of $59 Million
2026-07-27 20:00 · Yahoo
CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside?
2026-07-23 17:19 · Yahoo
2 Microcaps With Gross Margin Catalysts
2026-07-23 04:58 · Yahoo
Zacks Initiates Coverage of Champions Oncology With Neutral Recommendation
2026-07-22 14:13 · Yahoo
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Monday, July 27, 2026
2026-07-20 20:30 · Yahoo
Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026
2026-04-09 17:40 · Yahoo
Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy
2026-03-30 14:55 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.